Open AccessImmune checkpoint inhibitors (Nivolumab)-induced enterocolitis demonstrated on 18Fluorine-fluorodeoxyglucose positron emission tomography-computed tomography
Author(s) -
Sharjeel Usmani,
Rashid Rasheed,
Fahad Marafi,
Fareeda Al Kandari
Publication year - 2019
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/ijnm.ijnm_141_18
Subject(s) - medicine , nivolumab , fluorodeoxyglucose , adverse effect , positron emission tomography , radiology , immunotherapy , cancer
Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed.